Skip to main content

Opposite response of lung adenocarcinoma and its choroidal metastases upon ramucirumab plus docetaxel therapy after immunotherapy: a case report


We report a unique case of advanced non-small cell lung cancer that exhibited the opposite response to its unilateral choroidal metastases upon ramucirumab plus docetaxel treatment. A combination of cisplatin, pemetrexed, and pembrolizumab was administered as first-line treatment, resulting in shrinkage of all the lesions. However, although the patient was continued on a course of pembrolizumab, all the lesions had recurred approximately two months later. Ramucirumab plus docetaxel, administered as sequential treatment, resulted in maintained shrinkage of the choroidal lesions, yet all the other lesions progressed. Ramucirumab may be a suitable therapy for choroidal metastases, especially if administered immediately after immunotherapy.

This is a preview of subscription content, access via your institution.

Fig. 1

Code Availability

Not applicable.


  1. Shields CL, Shields JA, Gross NE, Schwartz GP, Lally SE (1997) Survey of 520 eyes with uveal metastases. Ophthalmology 104(8):1265–1276.

    CAS  Article  PubMed  Google Scholar 

  2. Mathis T, Jardel P, Loria O et al (2019) New concepts in the diagnosis and management of choroidal metastases. Prog Retin Eye Res 68:144–176.

    Article  PubMed  Google Scholar 

  3. Huinen ZR, Huijbers EJM, van Beijnum JR, Nowak-Sliwinska P, Griffioen AW (2021) Anti-angiogenic agents—overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nat Rev Clin Oncol 18(8):527–540.

    Article  PubMed  Google Scholar 

  4. Amselem L, Cervera E, Díaz-Llopis M et al (2007) Intravitreal bevacizumab (Avastin) for choroidal metastasis secondary to breast carcinoma: short-term follow-up. Eye 21(4):566–567.

    CAS  Article  PubMed  Google Scholar 

  5. Tozuka T, Kitazono S, Sakamoto H et al (2020) Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment. Lung Cancer 144:71–75.

    Article  PubMed  Google Scholar 

  6. Brueckl WM, Reck M, Rittmeyer A et al (2020) Efficacy of docetaxel plus ramucirumab as palliative third-line therapy following second-line immune-checkpoint-inhibitor treatment in patients with non-small-cell lung cancer stage IV. Clin Med Insights Oncol 14:1179554920951358.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Li X, Liang Y, Wang J, Hu Z, Yuan ZL, Xie P (2021) Pembrolizumab for choroidal metastases from non-small cell lung cancer: a case report and literature review. Hum Vaccin Immunother.

    Article  PubMed  PubMed Central  Google Scholar 

Download references


The authors did not receive support from any organization for the submitted work.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Takayuki Shiroyama.

Ethics declarations

Conflict of interest

The authors have no relevant financial or non-financial interests to disclose.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Matsumoto, K., Shiroyama, T., Hashida, N. et al. Opposite response of lung adenocarcinoma and its choroidal metastases upon ramucirumab plus docetaxel therapy after immunotherapy: a case report. Angiogenesis 25, 147–149 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • Lung adenocarcinoma
  • Choroidal metastasis
  • Ramucirumab
  • Docetaxel
  • Case report